The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Open accessAbstract
mRNA vaccines have the potential to tackle many unmet medical needs that are unable to be addressed with conventional vaccine technologies. A potent and well-tolerated delivery technology is integral to fully realizing the potential of mRNA vaccines. Pre-clinical and clinical studies have demonstrated that mRNA delivered intramuscularly (IM) with first-generation lipid nanoparticles (LNPs) generates robust immune responses. Despite progress made over the past several years, there remains significant opportunity for improvement, as the most advanced LNPs were designed for intravenous (IV) delivery of siRNA to the liver. Here, we screened a panel of proprietary biodegradable ionizable lipids for both expression and immunogenicity in a rodent model when administered IM. A subset of compounds was selected and further evaluated for tolerability, immunogenicity, and expression in rodents and non-human primates (NHPs). A lead formulation was identified that yielded a robust immune response with improved tolerability. More importantly for vaccines, increased innate immune stimulation driven by LNPs does not equate to increased immunogenicity, illustrating that mRNA vaccine tolerability can be improved without affecting potency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which are known to have significantly higher delivery efficiency in hepatocytes after intravenous (i.v.) injection31 or in muscle cells after intramuscular (i.m.) injection.32”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [32]
In the citing paper
“Based on these observations, Moderna has developed an ionizable lipid (namely Lipid H, SM-102), whose tail adopts larger branches which in turn increases potency, and whose introduced ester bonds increase biodegradability (Fig. 7).290,291”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [291]
In the citing paper
“All three major players in the mRNA vaccine field have previously optimized so-called lipid nanoparticles (LNPs), constructs that typically consist of an ionizable lipid and one or more helper lipids to improve LNP stability and promote endosomal escape upon cellular uptake [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“For Moderna's LNP formulation, Hassett et al. reported that the SM-102 lipid was selected based on its improved tolerability profile in non-human primates, as evidenced by a reduced local reactogenicity (e.g., edema and erythema) and lowest induction of systemic cytokine responses (e.g., IL-6) [13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“the usage of the SM-102 lipid in Moderna's mRNA-1273 vaccine was found to outperform Onpattro's MC3 LNPs for the intramuscular (i.m.) delivery of mRNA in rodents and non-human primates, given its improved tolerability and higher endosomal escape efficiency [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“Endosomal escape can be increased by optimizing the pKa values of ionizable lipids66,76–78,88,100,140.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“To improve the biocompatibility of lipid nanoparticles, biodegradable lipids can be applied76–78,108,179.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“Moreover, the delivery efficacy of mRNA could be improved, for example, by rational design of lipids through modulation of head groups and hydrophobic tails to increase cellular uptake and endosomal escape of lipid nanoparticle–mRNA formulations64,66,76–78,88,97,100,114,140,141.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Lanciotti, R. S., Kosoy, O. L., Laven, J. J., Velez, J. O., Lambert, A. J., Johnson, A. J., Stanfield, S. M., & Duffy, M. R. (2008) · Emerging infectious diseases · doi:10.3201/eid1408.080287 · Cited by 2,173
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“8.(11,13,23) However, the best lipids with respect to protein expression after IV administration generally had lower pKas than the best lipids for protein expression after IM administration.”
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Edward Jenner and the History of Smallpox and Vaccination
Riedel, S. F. (2005) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2005.11928028 · Cited by 965
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Self-citationZika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 918
Foley, R. A., Sims, R. A., Duggan, E. C., Olmedo, J. K., Ma, R., & Jonas, S. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.973326 · Cited by 60
Development and applications of mRNA treatment based on lipid nanoparticles
Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 57
Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines
Anderluzzi, G., Lou, G., Gallorini, S., Brazzoli, M., Johnson, R., O’Hagan, D. T., Baudner, B. C., & Perrie, Y. (2020) · Vaccines · doi:10.3390/vaccines8020212 · Cited by 57
Messenger RNA vaccines for cancer immunotherapy: progress promotes promise
Huff, A. L., Jaffee, E. M., & Zaidi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156211 · Cited by 60
mRNA vaccine designs for optimal adjuvanticity and delivery
Mochida, Y., & Uchida, S. (2024) · RNA Biology · doi:10.1080/15476286.2024.2333123 · Cited by 57
Abbasi, S., Matsui-Masai, M., Yasui, F., Hayashi, A., Tockary, T. A., Mochida, Y., Akinaga, S., Kohara, M., Kataoka, K., & Uchida, S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.022 · Cited by 56
Rational Design of Lipid Nanoparticles for Enhanced mRNA Vaccine Delivery via Machine Learning
Bae, S., Choi, H., Lee, J., Kang, M., Ahn, S., Lee, Y., Choi, H., Jo, S., Lee, Y., Park, H., et al. (2024) · Small · doi:10.1002/smll.202405618 · Cited by 55
Wang, L., Zhang, X., Yang, Z., Wang, B., Gong, H., Zhang, K., Lin, Y., & Sun, M. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00453-6 · Cited by 55
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang, Z., Peng, L., Filler, R. B., Suzuki, K., McNamara, A., Lin, Q., Renauer, P. A., Yang, L., Menasché, B. L., Sanchez, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30878-4 · Cited by 55
Biscaia-Caleiras, M., Fonseca, N. A., Lourenço, A. S., Moreira, J. N., & Simões, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.021 · Cited by 57
Li, Y., Tian, Y., Li, C., Fang, W., Li, X., Jing, Z., Yang, Z., Zhang, X., Huang, Y., Gong, J., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102518 · Cited by 57
Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning
Luo, J., Molbay, M., Chen, Y., Horvath, I., Kadletz, K., Kick, B., Zhao, S., Al-Maskari, R., Singh, I., Ali, M., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02528-1 · Cited by 53
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
Corbett, K. S., Werner, A. P., Connell, S. O., Gagné, M., Lai, L., Moliva, J. I., Flynn, B. J., Choi, A., Koch, M., Foulds, K. E., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01021-0 · Cited by 57
Targeting strategies for mRNA delivery
Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 55
He, Y., Zhang, W., Xiao, Q., Fan, L., Huang, D., Chen, W., & He, W. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.11.002 · Cited by 60
Lipid nanoparticles for RNA delivery: Self-assembling vs driven-assembling strategies
Nele, V., Campani, V., Moosavian, S. A., & Rosa, G. D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115291 · Cited by 58
Lu, Z., & Sun, D. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03890-8 · Cited by 53
Charge‐Conversion Strategies for Nucleic Acid Delivery
Dutta, K., Das, R., Medeiros, J., Kanjilal, P., & Thayumanavan, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011103 · Cited by 52
Design Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines
Liu, T., Tian, Y., Zheng, A., & Cui, C. (2022) · Polymers · doi:10.3390/polym14194195 · Cited by 54
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
Han, G., Noh, D., Lee, H., Lee, S., Kim, S., Yoon, H. Y., & Hyeon, L. S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114973 · Cited by 53
Intelligent Biomaterialomics: Molecular Design, Manufacturing, and Biomedical Applications
Yi, Y., An, H., & Wang, H. (2023) · Advanced Materials · doi:10.1002/adma.202305099 · Cited by 52
Steering the course of CAR T cell therapy with lipid nanoparticles
Khawar, M. B., Afzal, A., Si, Y., & Sun, H. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02630-1 · Cited by 54
Lv, K., Yu, Z., Wang, J., Li, N., Wang, A., Xue, T., Wang, Q., Shi, Y., Han, L., Qin, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202404684 · Cited by 53
Kawaguchi, Y., Kimura, M., Karaki, T., Tanaka, H., Ono, C., Ishida, T., Matsuura, Y., Hirai, T., Akita, H., Shimizu, T., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c10648 · Cited by 55
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
de Vyver, T. V., Smedt, S. C. D., & Raemdonck, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114041 · Cited by 51
Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective
Labouta, H. I., Langer, R., Cullis, P. R., Merkel, O. M., Prausnitz, M. R., Gomaa, Y. A., Nogueira, S. S., & Kumeria, T. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01146-1 · Cited by 52
Rational development of a combined mRNA vaccine against COVID-19 and influenza
Ye, Q., Wu, M., Chao Hui, Z. H. O. U., Lu, X., Huang, B., Zhang, N., Zhao, H. J., Chi, H., Zhang, X., Ling, D., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00478-w · Cited by 51
High‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications
Seo, H., Jeon, L., Kwon, J., & Lee, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203033 · Cited by 54
Stewart-Jones, G., Elbashir, S. M., Wu, K., Lee, D., Renzi, I., Ying, B., Koch, M., Sein, C. E., Choi, A., Whitener, B. M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf4100 · Cited by 55
Self-citationAnalytical techniques for the characterization of nanoparticles for mRNA delivery
Nogueira, S. S., Samaridou, E., Simon, J., Simon, F., Beck‐Broichsitter, M., & Mehta, A. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114235 · Cited by 57
Kubara, K., Yamazaki, K., Miyazaki, T., Kondo, K., Kurotaki, D., Tamura, T., & Suzuki, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.020 · Cited by 51
Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines
Wu, Y., Yu, S., & de Lázaro, I. (2024) · Nanoscale · doi:10.1039/d4nr00019f · Cited by 51
Advances in the design and delivery of RNA vaccines for infectious diseases
Lokras, A. G., Bobak, T. R., Baghel, S. S., Sebastiani, F., & Foged, C. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115419 · Cited by 52
Hwang, Y., Shepherd, S. J., Kim, D., Mukalel, A. J., Mitchell, M. J., Issadore, D. A., & Lee, D. (2024) · ACS Nano · doi:10.1021/acsnano.4c12965 · Cited by 50
The nanomedicine rush: New strategies for unmet medical needs based on innovative nano DDS
Sato, Y., Nakamura, T., Yamada, Y., & Harashima, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.032 · Cited by 50
Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies
Oliveira, G. S., Oliveira, M. L. S., Miyaji, E. N., & Rodrigues, T. C. (2021) · Vaccines · doi:10.3390/vaccines9111338 · Cited by 49
Pandemic-response adenoviral vector and RNA vaccine manufacturing
Kis, Z., Tak, K., Ibrahim, D., Papathanasiou, M. M., Chachuat, B., Shah, N., & Kontoravdi, C. (2022) · npj Vaccines · doi:10.1038/s41541-022-00447-3 · Cited by 52
Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 53
Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery
Haque, M. A., Shrestha, A., Mikelis, C. M., & Mattheolabakis, G. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100283 · Cited by 52
An Update on mRNA-Based Viral Vaccines
Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 49
Nanotheranostics against COVID-19: From multivalent to immune-targeted materials
Hassanzadeh, P. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.060 · Cited by 48
Forenzo, C., & Larsen, J. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00439 · Cited by 48
Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
Chuang, S. T., Conklin, B., Stein, J. B., Pan, G., & Lee, K. (2022) · Nano Convergence · doi:10.1186/s40580-022-00310-0 · Cited by 48
Takanashi, A., Pouton, C. W., & Al-Wassiti, H. A. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c01024 · Cited by 48
Xu, Y., Gong, F., Golubovic, A., Strilchuk, A. W., Chen, J., Zhou, M., Dong, S., Seto, B. Y., & Li, B. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409572122 · Cited by 49
Papi, M., Pozzi, D., Palmieri, V., & Caracciolo, G. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101403 · Cited by 46
Dehghani‐Ghahnaviyeh, S., Smith, M., Xia, Y., Dousis, A. D., Grossfield, A. M., & Sur, S. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c01296 · Cited by 47
Shi, R., Liu, X., Wang, Y., Pan, M., Wang, S., Shi, L., & Ni, B. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2342592 · Cited by 48
The dynamic process of mRNA delivery by lipid nanoparticles in vivo
Ma, R., Li, Y., Wei, Y., Zhou, J., Ma, J., Zhang, M., Tu, J., Jiang, J., Xie, S., Tan, W., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102325 · Cited by 46
Nanoscale delivery platforms for RNA therapeutics: Challenges and the current state of the art
Rhym, L. H., & Anderson, D. G. (2022) · Med · doi:10.1016/j.medj.2022.02.001 · Cited by 45
Yi, J., Lei, X., Guo, F., Chen, Q., Chen, X., Zhao, K., Zhu, C., Cheng, X., Lin, J., Yin, H., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105618 · Cited by 45
Zhang, W., Pfeifle, A., Lansdell, C., Frahm, G. E., Cecillon, J., Tamming, L. A., Gravel, C., Gao, J., Raman, S. N. T., Wang, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11101580 · Cited by 45
Zeng, Y., Sentí, M. E., Labonia, M. C. I., Papadopoulou, P., Brans, M. A. D., Dokter, I., Fens, M. H. A. M., van Mil, A., Sluijter, J. P. G., Schiffelers, R. M., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c05341 · Cited by 48
Gholap, A. D., Gupta, J., Kamandar, P. A., Bhowmik, D. D., Rojekar, S. V., Faiyazuddin, M., Hatvate, N. T., Mohanto, S., Ahmed, M. G., Subramaniyan, V., et al. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01247 · Cited by 45
From micro to nano: evolution and impact of drug delivery in treating disease
Hrkach, J., & Langer, R. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00769-6 · Cited by 45
Bioinspired Lipid Nanocarriers for RNA Delivery
Golubovic, A., Tsai, S., & Li, B. (2023) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.2c00073 · Cited by 49
Tanaka, H., Hagiwara, S., Shirane, D., Yamakawa, T., Sato, Y., Matsumoto, C., Ishizaki, K., Hishinuma, M., Chida, K., Sasaki, K., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c10501 · Cited by 44
Meulewaeter, S., Aernout, I., Deprez, J., Engelen, Y., Velder, M. D., Franceschini, L., Breckpot, K., Calenbergh, S. V., Asselman, C., Boucher, K. L., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.052 · Cited by 46
Petersen, D. M. S., Weiss, R. M., Hajj, K. A., Yerneni, S. S., Chaudhary, N., Newby, A. N., Arral, M. L., & Whitehead, K. A. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400225 · Cited by 46
Brook, B., Duval, V., Barman, S., Speciner, L., Sweitzer, C., Khanmohammed, A., Menon, M., Foster, K., Ghosh, P., Abedi, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adm8451 · Cited by 49
On-patient medical record and mRNA therapeutics using intradermal microneedles
Han, J., Kanelli, M., Liu, Y., Daristotle, J. L., Pardeshi, A., Forster, T. A., Karchin, A., Folk, B., Murmann, L., Tostanoski, L. H., et al. (2025) · Nature Materials · doi:10.1038/s41563-024-02115-4 · Cited by 44
Fine-tuning of polyaspartamide derivatives with alicyclic moieties for systemic mRNA delivery
Yum, J., Kim, B. S., Ogura, S., Kamegawa, R., Naito, M., Yamasaki, Y., Kim, H. J., & Miyata, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.040 · Cited by 43
Rohde, C. M., Lindemann, C., Giovanelli, M. A., Sellers, R. S., Diekmann, J., Choudhary, S., Ramaiah, L., Vogel, A. B., Chervona, Y., Muik, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11020417 · Cited by 44
Therapeutic synthetic and natural materials for immunoengineering
Slezak, A., Chang, K., Hossainy, S., Mansurov, A., Rowan, S. J., Hubbell, J. A., & Guler, M. O. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00805c · Cited by 44
Lipid Nanoparticle-Based Delivery SystemA Competing Place for mRNA Vaccines
Zhang, X., Li, Y., & Zhou, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c08353 · Cited by 43
Gyanani, V., & Goswami, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041184 · Cited by 42
High-throughput platforms for machine learning-guided lipid nanoparticle design
Hanna, A. R., Issadore, D., & Mitchell, M. J. (2025) · Nature Reviews Materials · doi:10.1038/s41578-025-00831-0 · Cited by 49
Ishaqat, A., & Herrmann, A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08484 · Cited by 42
Francis, J. E., Skakic, I., Dekiwadia, C. D., Shukla, R., Taki, A. C., Walduck, A. K., & Smooker, P. M. (2020) · Vaccines · doi:10.3390/vaccines8030551 · Cited by 41
Lofano, G., Mallett, C. P., Bertholet, S., & O’Hagan, D. T. (2020) · npj Vaccines · doi:10.1038/s41541-020-00238-8 · Cited by 41
Bartesaghi, S., Wallenius, K., Hovdal, D., Liljeblad, M., Wallin, S., Dekker, N., Barlind, L., Davies, N. M., Seeliger, F., Winzell, M. S., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.010 · Cited by 40
Self-citationPatel, N., Davis, Z., Hofmann, C., Vlasak, J., Loughney, J. W., DePhillips, P. A., & Mukherjee, M. (2023) · Vaccines · doi:10.3390/vaccines11071224 · Cited by 42
A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety
Bae, S., Yoo, S., Lee, J. S., Park, H., Kwon, S. P., Jin, H., Park, S., Lee, Y., Bang, Y., Roh, G., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.05.012 · Cited by 41
A perspective on the apparent pKa of ionizable lipids in mRNA-LNPs
Simonsen, J. B., & Larsson, P. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113879 · Cited by 41
da Trindade, L. R., da Silva, D. V. T., Baião, D. D. S., & Paschoalin, V. M. F. (2021) · Molecules · doi:10.3390/molecules26154621 · Cited by 42
Microfluidics for Development of Lipid Nanoparticles: Paving the Way for Nucleic Acids to the Clinic
Ali, M. S., Hooshmand, N., El‐Sayed, M. A., & Labouta, H. I. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00732 · Cited by 40
SARS-CoV-2 Vaccine Development: An Overview and Perspectives
Liu, Y., Wang, K., Massoud, T. F., & Paulmurugan, R. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00109 · Cited by 40
Ci, L., Hard, M., Zhang, H., Gandham, S. K., Hua, S. S., Wickwire, J., Wehrman, T., Slauter, R., Auerbach, A. D., Kenney, M., et al. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.000980 · Cited by 39
Self-citationRational design of lipid nanoparticles for enabling gene therapies
Brimacombe, C. A., Kulkarni, J. A., Cheng, M. H. Y., An, K., Witzigmann, D., & Cullis, P. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101518 · Cited by 45
Huang, X., Chuang, L. I. U., Sharma, S. N., You, X., Chen, S., Li, Y., Liu, H.-J., Liu, B., Saiding, Q., Chen, W., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu1493 · Cited by 39
mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
Chavda, V. P., Jogi, G., Dave, S., Patel, B. M., Nalla, L. V., & Koradia, K. D. (2023) · Vaccines · doi:10.3390/vaccines11030507 · Cited by 39
Alshehry, Y., Liu, X., Zhang, Y., & Zhu, G. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113617 · Cited by 39
Nucleic Acid Delivery from Granular Hydrogels
Kurt, E., & Segura, T. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101867 · Cited by 39
Exosome-Mediated mRNA Delivery For SARS-CoV-2 VaccinationPreprint
Tsai, S. J., Guo, C., Sedgwick, A., Kanagavelu, S. K., Nice, J. B., Shetty, S., Landaverde, C., Atai, N. A., & Gould, S. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.06.371419 · Cited by 38
Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity
Provine, N. M., & Klenerman, P. (2022) · European Journal of Immunology · doi:10.1002/eji.202250022 · Cited by 37
Regulatory Considerations on the Development of mRNA Vaccines
Naik, R., & Peden, K. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_220 · Cited by 37
Ding, F., Zhang, H., Cui, J., Li, Q., & Yang, C. (2021) · Biomaterials Science · doi:10.1039/d1bm00866h · Cited by 37
Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles
Lewis, M. M., Soto, M. R., Maier, E. Y., Wulfe, S., Bakheet, S., Obregon, H., & Ghosh, D. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10580 · Cited by 36
Lin, W.-Z. S., Bostic, W. K. V., & Malmstadt, N. (2023) · Lab on a Chip · doi:10.1039/d3lc00520h · Cited by 36
Design principles of lipid nanoparticles for RNA delivery
Arral, M. L., & Whitehead, K. A. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00401-1 · Cited by 41
mRNA Synthesis and Encapsulation in Ionizable Lipid Nanoparticles
McKenzie, R. E., Minnell, J. J., Ganley, M., Painter, G. F., & Draper, S. L. (2023) · Current Protocols · doi:10.1002/cpz1.898 · Cited by 38
An overview of lipid constituents in lipid nanoparticle mRNA delivery systems
Wu, S., Lin, L., Shi, L., & Liu, S. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1978 · Cited by 35
Kudsiova, L., Lansley, A. B., Scutt, G., Allen, M. C., Bowler, L. D., Williams, S., Lippett, S., Stafford, S., Tarzi, M. D., Cross, M., et al. (2021) · BMJ Open Science · doi:10.1136/bmjos-2021-100203 · Cited by 35
In Vitro Models of Biological Barriers for Nanomedical Research
Carton, F., & Malatesta, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168910 · Cited by 34
Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines
Bolhassani, A. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00624-8 · Cited by 36
Ronk, A. J., Lloyd, N. M., Zhang, M., Atyeo, C. G., Perrett, H. R., Mire, C. E., Hastie, K. M., Sanders, R. W., Brouwer, P. J. M., Saphire, E. O., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41376-6 · Cited by 36
Self-citationTirelli, C., AMICI, M. D., Albrici, C., Mira, S., Nalesso, G., Re, B., Corsico, A. G., Mondoni, M., & Centanni, S. (2023) · Biology · doi:10.3390/biology12020177 · Cited by 35
Development of nucleic acid medicines based on chemical technology
Kawamoto, Y., Wu, Y., Takahashi, Y., & Takakura, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114872 · Cited by 34
AboulFotouh, K., Southard, B., Dao, H. M., Xu, H., Moon, C., Williams, R. O., & Cui, Z. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123688 · Cited by 34
Lombaerde, E. D., Chen, Y., Ye, T., Deckers, J., Mencarelli, G., Swarte, K. D., Lauwers, H., Coen, R. D., Kasmi, S., Bevers, S., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202310623 · Cited by 36
Metadata
- Authors
- Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., Mihai, C., Lynn, A., McFadyen, I., Moore, M. J., Senn, J. J., Stanton, M. G., Almarsson, Ö., Ciaramella, G., & Brito, L. A.
- Affiliations
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Brito, Luis A.
- ORCID
- Venue
- Molecular Therapy — Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 15
- Pages
- 1-11
- ISSN
- 2162-2531 (ISSN-L)
- PMC
- PMC6383180
- OpenAlex
- W2914060533
- Cited by
- 927
- References
- 35
- Citations by year
- 2026: 141 · 2025: 202 · 2024: 162 · 2023: 140 · 2022: 128 · 2021: 114 · 2020: 35 · 2019: 5
- FWCI
- 23.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecular Therapy — Nucleic Acids (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Moderna Therapeutics
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- lipid nanoparticles, mRNA vaccines, intramuscular administration, ionizable lipids, biodegradable lipids, immunogenicity, tolerability, innate immune activation, non-human primates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
